Outcome in ulcerative colitis after switch from Adalimumab/Golimumab to infliximab: A multicenter retrospective study

anti-TNF therapies Infliximab (IFX), Adalimumab (ADA), and Golimumab (GOL) are approved for treating moderate to severe ulcerative colitis (UC). In UC, only the switch from IFX to ADA has been investigated, reaching no more than 10–43% remission rates at 12 months.

from Gastroenterology via xlomafota13 on Inoreader https://ift.tt/2Pt0xfM
via IFTTT